Trial Profile
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Apremilast (CC-10004) in Pediatric Subjects from 6 through 17 Years of Age with Moderate to Severe Plaque Psoriasis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms SPROUT
- Sponsors Amgen; Celgene Corporation
- 12 Mar 2024 According to an Amgen media release, the company announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla (apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego
- 14 Nov 2023 Status changed from completed to discontinued.
- 28 Mar 2023 Status changed from active, no longer recruiting to completed.